PFIZER INC Earnings Summary — Q1 2026

• Revenue grew 5.37% YoY to $14.45 billion, signaling a stabilization in the top line after the COVID-19 franchise peak.
• Operating income rose to $3.17 billion, reflecting early benefits from the 'Lighten the Load' cost-realignment program.
• R&D investment remains substantial at $2.63 billion (18% of revenue) to support the post-Seagen oncology pipeline.
• The company reported a quarterly net income of $2.71 billion, a significant recovery from the loss reported in Q4 2025.
• Non-COVID product growth is becoming the primary driver as Comirnaty and Paxlovid normalize to baseline levels.
• Total operating expenses decreased slightly to $7.73 billion compared to the prior-year period as synergies begin to materialize.

Management remains focused on the 'Lighten the Load' cost-realignment program aiming for $4 billion in annual savings and the integration of Seagen to drive long-term oncology growth.

Improving

A return to positive YoY revenue growth and a swing back to profitability from the prior quarter's loss indicates the transition phase is gaining traction.

The company is pivoting toward a post-pandemic era dominated by oncology and rare diseases, though it faces multi-year headwinds from upcoming loss of exclusivity on legacy blockbusters.